DiagnaMed Holdings Corp. · CSE:DMED
DiagnaMed — Investor Presentation (December 2024)
13 slides from DiagnaMed's investor presentation, December 2024
Slide 1: DiagnaMed Holdings Corp. Corporate Presentation
DiagnaMed Holdings Corp. Corporate Presentation DECEMBER 2024 CSE: DMED | OTCQB: DGNMF
Slide 2: Developing Emerging Hydrogen Producing Technologies
Developing Emerging Hydrogen Producing Technologies DiagnaMed
Slide 3: Team
Team Experienced in capital raising, product development and commercialization for life sciences, natural resources and cleantech sectors Fabio Chianelli Jing Peng, CPA Chairman and CEO Chief Financial Officer Current and Past Current and Past CEO - PharmaTher FuelPositive Corporation President - Re
Slide 4: Technology Incubation
Technology Incubation Medical Hydrogen Water to Hydrogen Evaluation DiagnaMed
Slide 5: Converting Water to Hydrogen
Converting Water to Hydrogen DiagnaMed
Slide 6: EIREX Technology
EIREX Technology Collaboration with EIREX in developing a novel modular carbon-free technology that extracts hydrogen from water Solving the problems faced by producing hydrogen via electrolysis Scalable solution will offer on-site hydrogen EIREX’s approach uses the unique production in various size
Slide 7: EIREX Key Benefits
EIREX Key Benefits Low Cost: Produces hydrogen at less than 1.4 kWh per kg, significantly reducing costs. On-Demand: Minimizes hydrogen storage requirements. On-Site Production: Eliminates the need for extensive distribution infrastructure. Self-Powered: Operates without reliance on external grid en
Slide 8: Unlocking the Medical Potential of Hydrogen
Unlocking the Medical Potential of Hydrogen DiagnaMed
Slide 9: Molecular Hydrogen
Molecular Hydrogen Molecular hydrogen therapy is a rapidly growing field and poised for clinical adoption Over 2,000 scientific publications on potential therapeutic effects in over 100 human studies Clinically demonstrated to provide antioxidant, anti-inflammatory and neuroprotective effects Potent
Slide 10: Limitations of Molecular Hydrogen
Limitations of Molecular Hydrogen Clinical use is limited Low hydrogen content Rapid evaporating action in water Lower effective concentration and poor stability Hydrogen inhalation and hydrogen-rich water machines Expensive, bulky and complex to use Challenge to determine appropriate dosage for des
Slide 11: Our Solution
Our Solution HydroPharm Novel ‘patent-pending’ oral molecular hydrogen tablet tailored for mental health Hydrogen producing and neurological disorders oral tablets HydroGas Natural hydrogen to meet the diverse needs of patients and life sciences industry Hydrogen gas for medical use DiagnaMed
Slide 12: Financial Snapshot
Financial Snapshot 81,408,640 Common Shares outstanding 1,770,000 4,500,000 @ $0.10, expire Jan 4, 2027 @ $0.05, expire Nov 13, 2029 Stock Options ~ 21% Insider Ownership DiagnaMed
Slide 13: Thank You
THANK YOU DiagnaMed Holdings Corp. 82 Richmond Street East Toronto, ON M5C 1P1 t. 416-800-2684 e. info@diagnamed.com w. diagnamed.com DiagnaMed
DiagnaMed Holdings — Investor Presentation (December 2024) on 6ix